OMB No. 0925-0001 and 0925-0002 (Rev. 11/16 Approved Through 10/31/2018)

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.  
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Faisal Latif

eRA COMMONS USER NAME (credential, e.g., agency login): FLATIF

POSITION TITLE: Associate Professor of Medicine (University of Oklahoma Health Sciences Center); Director, Cardiac Catheterization Laboratory (Oklahoma City VA Medical Center)

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)

| INSTITUTION AND LOCATION | DEGREE  (if applicable) | Completion Date  MM/YYYY | FIELD OF STUDY |
| --- | --- | --- | --- |
| King Edward Medical College  Lahore, Pakistan | M.B., B.S. | 1994-2000 | Medical Degree |
| Masood Hospital  Lahore, Pakistan | Residency | 7/1/00 -11/30/01 | General Medicine |
| University of Oklahoma Health Sciences Center  Oklahoma City, OK | Residency | 7/1/02 -6/30/05 | Internal Medicine |
| University of Oklahoma Health Sciences Center  Oklahoma City, OK | Fellowship | 7/1/05 -6/30/08 | Cardiovascular Diseases |
| William Beaumont Hospital  Royal Oak, Michigan | Fellowship | 7/1/08-6/30/09 | Interventional Cardiology |

**A. Personal Statement**

**As an educator and an Interventional Cardiologist, my clinical and research focus has been on advancement of clinical care before and after coronary and vascular interventions to bring about meaningful improvement in patient’s quality of life as well as prevention of complications. I have received a Pilot grant, which has been completed and a follow-up study is in planning phase. Focusing on the health of patients with cardiovascular disease, I have spent a considerable amount of effort in participating in multicenter randomized trials with sizeable patient recruitment. Improving quality of care has also been my passion and I have published in scientific journals including Journal of American College of Cardiology, Catheterization and Cardiovascular Interventions among others. Writing books I have used writing books as a vehicle to disseminate procedural techniques. I have written numerous book chapters and co-edited a book on Management of Complex Cardiovascular Problems, which has been quite popular on Amazon. I serve on various committees with national societies including American College of Cardiology, and Society of Cardiovascular Angiography & Interventions. Serving as the Governor of Oklahoma Chapter of ACC has been an honor. Below are some selected publications:**

**1. Naidu SS, Aronow HD, Box LC, Duffy PL, Kolansky DM, Kupfer JM, Latif F, et al. SCAI Expert Consensus Statement: 2016 Best Practices in the Cardiac Catheterization Laboratory. Catheter Cardiovasc Interv. 2016 Sep;88(3):407-23.**

**2. Wayangankar S, Bangalore S, McCoy L, Jneid H, Latif F, et al. Temporal Trends and Outcomes of Patients Undergoing Percutaneous Coronary Interventions for Cardiogenic Shock in the Setting of Acute Myocardial Infarction: A Report from the CathPCI Registry. JACC Cardiovasc Interv. 2016 Feb 22;9(4):341-351.**

**3. Latif F, Brilakis ES, Exaire JE. Retrograde Approach to Successfully Treat Antegrade Failure Due to Subintimal Hematoma of a Right Coronary Artery Chronic Total Occlusion. Interv. Cardiol. 2015; 7(3), 229–233.**

**4. Christopoulos G, Christakopoulos GE, Rangan BV, Layne R, Grabarkewitz R, Haagen D, Latif F, Abu-Fadel M, Banerjee S, Brilakis ES. Comparison of Radiation Dose Between Different Fluoroscopy Systems in the Modern Catheterization Laboratory: Results from Bench Testing Using an Anthropomorphic Phantom. Catheter Cardiovasc Interv. 2015 Nov;86(5):927-32. Epub 2015 May 23. Erratum in: Catheter Cardiovasc Interv. 2016 Jun;87(7):1364.**

**7. Wayangankar SA, Kennedy KF, Aronow HD, Rundback J, Tafur A, Drachman D, Patel B, Sivaram CA, Latif F. Racial/Ethnic Variation in Carotid Artery Revascularization Utilization and Outcomes: Analysis from the National Cardiovascular Data Registry. Stroke. 2015 Jun;46(6):1525-32. Epub May 7.**

**8. Seto AH, Roberts JS, Abu-Fadel MS, Czak SJ, Latif F, Jain SP, Raza JA, Mangla A, Panagopoulos G, Patel PM, Kern MJ, Lasic Z. Real-Time Ultrasound Guidance Facilitates Transradial Access: RAUST (Radial Artery Access with Ultrasound Trial). JACC Cardiovasc Interv. 2015 Feb;8(2):283-91. Epub 2015 Jan 14.**

**B. Positions and Honors**

**Positions and Employment**

7/1/2015 to present Associate Professor of Medicine, Cardiovascular Section

University of Oklahoma Health Sciences Center, Oklahoma City, OK

7/27/2009 to 6/30/2015 Assistant Professor of Medicine, Cardiovascular Section

University of Oklahoma Health Sciences Center, Oklahoma City, OK

7/1/2013 to present Associate Program Director, Cardiology Fellowship Program

University of Oklahoma Health Sciences Center, Oklahoma City, OK

9/2009 to 6/2015 Medical Director, Nuclear Cardiology Department

OU Physicians, Heart Lung & Vascular Center, Oklahoma City, OK

7/1/2013 to present Director, Cardiac Cath Lab, VA Medical Center, Oklahoma City, OK

7/1/2011 to 8/15/2013 Director, Coronary Care Unit, VA Medical Center, Oklahoma City, OK

7/27/2009 to present Staff Cardiologist, VA Medical Center, Oklahoma City, OK

**Other Experience and Professional Memberships**

2017-Present American College of Cardiology (ACC) Governor of Oklahoma Chapter

2016-Present Member MedSurg DMC, Hines VA, Illinois

2016-Present Executive Committee Member, VA Cooperative CCTA Trial #0002

2016-Present Member, National Cardiovascular Data Registry’s Peripheral Vascular Interventions (NCDR PVI) Research & Publications Committee

2015-Present American College of Cardiology (ACC) Exhibits Subcommittee

October 2014 Representative of Society of Cardiovascular Angiography & Interventions at Great Wall International Congress of Cardiology, Beijing, China

October 2014 Representative of Society of Cardiovascular Angiography & Interventions at Vietnam National Congress of Cardiology, Da Nang City, Vietnam

2013-2017 Society for Cardiovascular Angiography & Interventions (SCAI) Carotid Stenting Committee.

Society for Cardiovascular Angiography & Interventions (SCAI) International Programs & Membership Committee.

5/10/2013 to present Society for Cardiovascular Angiography & Interventions (SCAI) Quality Improvement Committee

2006-2009 National Member American College of Cardiology Fellows in Training (ACC FIT)

Committee Workgroup on Training Program Initiatives

**Honors**

April 2017 James F. Hammarsten Physician of Excellence Award, Oklahoma City VA

Healthcare System

2016 Inducted into the Academy of Teaching Scholars, University of Oklahoma HSC

2017-2020 American College of Cardiology (ACC) Governor of Oklahoma

2015 Provost’s Research Award Junior Faculty, University of Oklahoma HSC

September 2014 Selected to participate in American College of Cardiology (ACC) Teaching Skills

Workshop for Emerging Faculty, Washington DC

7/2012 to 6/2013 Faculty Fellow in Faculty Leadership Program at University of Oklahoma HSC

2006-2007 Listed as an Honored Member Manchester Who’s Who Registry of Executives

and Professionals

2006 Winner of Special Prize for Case Presentation at ACCP Annual Scientific

Sessions 2006

2006 First Prize for Poster Presentation at ACP-ASIM Oklahoma Chapter Meeting

**C. Contributions to Science**

**1. The POPICS Randomized Pilot Study: Peri-Operative medical management versus Prophylactic coronary revascularization plus medical management In patients with positive myoCardial perfusion scan undergoing moderate to high risk non-cardiac Surgery. Pre-operative management of patients with symptomatic coronary artery disease before non-cardiac surgery has been my major interest. I was awarded research grant of $100,000 by South Central VA Health Care Network (SCVAHN) Research Grants Program and served as the Principal Investigator for the study. One-year follow-up of all study patients was recently completed and a final manuscript is in progress. Study results have been presented at the annual scientific sessions of Society of Cardiovascular Angiography & Interventions (SCAI). I am writing a grant for a follow-up study on this subject to be started as a multicenter trial with inclusion of biomarkers which could help predict adverse peri-operative cardiovascular outcomes in this patient population and therefore could benefit from revascularization.**

1. Latif F, Wayangankar SA, Aston CE, Dib C, Abu-Fadel MS, Lozano PM, Exaire JE, Ali M, Ramirez-Jimenez A, Thadani U. Outcomes of Conservative versus Invasive approach pre-operatively after abnormal myocardial perfusion scan: A Randomized Veterans’ Pilot Study. SCAI 2016 Scientific Sessions, May 2016, Orlando, FL.
2. Rahat T, Nguyen T, **Latif F**. Role of Prophylactic Coronary Revascularisation in Improving Cardiovascular Outcomes During Non-Cardiac Surgery: A Narrative Review. Neth Heart J. 2016 Oct;24(10):563-70. [PMID: 27538928]

2. **PREMIER Trial (CCTA#0002; VA funded at >$100,000/year): Plaque regression and progenitor cell mobilization with intensive lipid elimination regimen**: This study randomized patients to LDL-apheresis + statins.vs. Statins. Phase 1 has been completed while phase 2 is in follow-up phase. We met 95% of our recruitment target. I participated in both phases, and the Site Investigator and serve on the Executive Committee of the PREMIER randomized controlled trial. The study was planned for initiation and completion of enrollment in 2015 and 2018, respectively has met all its pre-specified benchmarks and its results are expected in October 2018. In addition, the Dallas VA Medical Center met 100% of its required enrollments. An independent data safety monitoring board and U.S. Food and Drug Administration oversight of the study has thus far not cited any major violations of the study protocol or patient safety concerns.

3. **Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty (DIVA; NCT01121224):** At the VA Medical Center, I care for veterans’ with a high prevalence of CABG surgery who therefore, need stenting procedures in their saphenous vein grafts. DIVA was the ideal study to be performed in this patient population. It is funded by the VA Cooperative Study Program (CSP 571). I served as a Site Principal Investigator for DIVA study. When the study was handed over to me, we were struggling with our site enrollment and were on probation due to low recruitment. With personal interest and hard work, we improved out recruitment significantly to finish seventh out of 25 VA sites. The final study results have been presented at the annual scientific sessions of European Society of Cardiology 2017 and the final manuscript is about to be submitted to a very high impact journal. An independent data safety monitoring board of the study did not cite any major violations of the study protocol or patient safety concerns.

1. Brilakis ES, Banerjee, **Latif F**, et al. Drug Eluting Stents vs. Bare Metal Stents in Saphenous Vein Grafts. Presented to European Society of Cardiology, August 2017.

4. **PRESERVE Trial (VA CSP#578): Prevention of Serious Adverse Events Following Angiography**

**IV Normal Saline vs IV Sodium Bicarbonate & N-Acetylcysteine vs Placebo for prevention of Contrast-induced Nephropathy (04/29/14 to present - Prospective, double-blind RCT):** Acute kidney injury following coronary and vascular procedures has been associated with increased risk of mortality. We participated in the largest trial evaluating the two types of IV fluids and enrolled approximately 130 patients in this study. I served as the site principal investigator. The study is in follow-up phase. An independent data safety monitoring board of the study did not cite any major violations of the study protocol or patient safety concerns.

**Book Chapters**

1. Latif F, Brachial Artery Access. In Abu-Fadel M. (Ed.), Chapter 5, *Arterial and Venous Access in the Cardiac Catheterization Lab*. Rutgers University Press. June 2016.
2. Rousan TA, **Latif F** (2014). Optical Coherence Tomography: Current Utility and Future Potential for Management of In-Stent Restenosis. In Amir Lotfi (Ed.), *Coronary Artery Restenosis: Causes, Treatment and Clinical Outcomes*. Hauppauge, NY: Nova Science Publishers, Inc.
3. Thadani U, **Latif, F**. What is the Optimal Therapy for Stable Angina/Ischemic Heart Disease in 2013? International Congress on Coronary Artery Disease 2013;229-232.
4. Chaudhry MA, Omar Z, **Latif F** (2013). Impact of Renal Dysfunction and Peripheral Arterial Disease on Post-Operative Outcomes After Coronary Artery Bypass Grafting. In W. Aronow (Ed.), *Artery Bypass*. Intech Publishers. ISBN 980-953-307-970-2.
5. **Latif F**, Sanghvi K, Grines CL (2011). Healthcare Delivery for Primary Angioplasty: The North American Model. In S Brecker, M Rothman (Eds.), *Essential Concepts of Primary Angioplasty* (Chapter 16b, pp. 170-175). New York: Informa Healthcare. ISBN 9781841846736.

**D. Additional Information: Research Support and/or Scholastic Performance**

**Current**

PRESERVE Ancillary (VA CSP#578) - Site Principal Investigator

Biomarker collection and analysis in the Preserve trial cohort

CLOPIDOGREL ADHERENCE - Site Principal Investigator - 09/2015 to Present

Hybrid Effectiveness-Implementation Study to Improve Clopidogrel Adherence (VA Study)

XL-PAD Registry - Sub-Investigator - 11/4/12 to present

Multicenter Registry for Peripheral Arterial Disease Interventions and Outcomes. PAD below the knee and superficial femoral artery interventions and outcomes.

EUCLID SUB-STUDY – Site Co-Principal Investigator - 03/2013 to Present

Industry - AstraZeneca

Effect of Ticagrelor versus Clopidogrel for Inhibition of Platelet Activity in Subjects with Symptomatic Peripheral Artery Disease: EUCLID Platelet Function Substudy

JETSTREAM ISR – Sub-Investigator - 10/2016 to present

Industry- Midwest Cardiovascular Research Foundation (MCRF)

JetStream Atherectomy for the Treatment of In-stent Restenosis of the Femoropopliteal Artery (JET ISR Trial)

ODYSSEY – Sub-Investigator - 12/2013 to present

Industry – Sanofi

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

SAVI-PCI – Sub-Investigator - 07/2012-Present

Industry – Medicure International, Inc.

A Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy of Tirofiban Using a High-Dose Bolus Plus a Shortened Infusion Duration Versus Label-Dosing Eptifibatide in Patients Undergoing Percutaneous Coronary Intervention